SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma informs about ESG ratings

21 Mar 2026 Evaluate

Piramal Pharma has informed that as per the information received by the Company on March 20, 2026, SES ESG Research (‘SES ESG’), has assigned an Environment, Social and Governance (‘ESG’) Rating of ‘68.5’ for the Company for FY 2024-25 based on data made available by the Company in public domain for that year. The link for the rating as published is also available on the website. The Company has not engaged SES ESG for ESG Rating. SES ESG has voluntarily prepared the report considering the ESG factors reported by the Company. This intimation is also being uploaded on the website of the Company at https://www.piramalpharma.com/.

The above information is a part of company’s filings submitted to BSE.

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×